Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 14/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 14/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 14/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medroxalol SCHEMBL30371313 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Medroxalol SCHEMBL31058839 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Medroxalol SCHEMBL588175 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11881655 | 0.90 | ADRB2 (0.98) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11467502 | 0.88 | ADRB1 (0.98) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL11447743 | 0.87 | ADRB1 (1.00) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL3719742 | 0.83 | ADRB2 (0.84) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL3719745 | 0.82 | ADRB2 (0.82) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL13284845 | 0.82 | ADRB2 (0.80) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Labetalol SCHEMBL41231 | 0.82 | ADRB1 (1.00) | ADRB2ADRB1ADRB3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 953 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| EP-4547331-A1 | THERAPEUTIC APPLICATIONS BASED ON THE INHIBITION OF G PROTEIN-COUPLED RECEPTOR 182 (GPR182) | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-05-07 | — | — | EP | claimed |
| EP-4473964-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Dr.Noah Biotech Inc. (KR) | 2024-12-11 | — | — | EP | claimed |
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | DR.NOAH BIOTECH INC. (KR) | 2024-05-09 | — | — | US | claimed |
| WO-2024003131-A1 | THERAPEUTIC APPLICATIONS BASED ON THE INHIBITION OF G PROTEIN-COUPLED RECEPTOR 182 (GPR182) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-01-04 | — | — | WO | claimed |
| EP-4299119-A1 | THERAPEUTIC APPLICATIONS BASED ON THE INHIBITION OF G PROTEIN-COUPLED RECEPTOR 182 (GPR182) | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-01-03 | — | — | EP | claimed |
| WO-2023149682-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | 닥터노아바이오텍 주식회사 | 2023-08-10 | — | — | WO | claimed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | claimed |
| US-6495154-B1 | ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS | VIVUS INC. | 2002-12-17 | — | — | US | claimed |
| EP-1261373-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SmithKline Beecham plc (GB) | 2002-12-04 | — | — | EP | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| WO-2001047509-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| EP-0105996-A1 | Ophthalmic compositions for treating elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ACHE, BACE1, CHRNB4 | ADRB2 11/4885ADRB1 7/4885ADRB3 12/4885 |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | ADRB2 677/4885ADRB1 630/4885ADRB3 557/4885 |
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | GPR132, GPR142, FAM162A | ADRB2 60/4885ADRB1 31/4885ADRB3 80/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | ADRB2 747/4885ADRB1 886/4885ADRB3 420/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | ADRB2 246/4885ADRB1 309/4885ADRB3 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.